Overcoming BRAF and CDK4/6 Inhibitor Resistance by Inhibiting MAP3K3-Dependent Protection Against YAP Lysosomal Degradation

Researchers identified MAP3K3 as a target for overcoming anticancer drug resistance. Depletion of MAP3K3 led to a substantial reduction in the yes-associated protein (YAP) protein level in melanoma and breast cancer cells.